Energy, Cognition & Mood
Peptides for PTSD & Trauma Recovery: Evidence vs Hype (2026)
An evidence-graded look at the three peptides marketed for PTSD and trauma — oxytocin, Selank and Semax — separating the mixed human oxytocin RCTs from anxiety-only and preclinical claims.
OxytocinSelankSemaxFear extinctionTrauma recovery
The quick verdict
No peptide is a proven PTSD treatment. Of the three most marketed for trauma, only oxytocin has been tested in PTSD patients in randomized trials — and even there the evidence is mixed and contested. We grade each honestly against the human record.
- Best overall
- Oxytocin (intranasal) — The only peptide tested in actual PTSD patients in randomized trials. The evidence is genuinely mixed — a pilot augmentation trend, a positive provoked-symptom crossover, and a negative prevention RCT — which earns it Grade B and the top spot as an experimental adjunct under study, not a treatment.
- Best value
- Selank — Has real human RCT evidence, but for generalized anxiety and neurasthenia rather than PTSD. If hyperarousal and anxiety are the dominant symptoms, its anxiolytic profile is the most human-supported of the non-oxytocin options — while remaining an extrapolation, not PTSD evidence (Grade C–D for PTSD).
- Best for Augmenting trauma-focused psychotherapy under clinical supervision
- Oxytocin (intranasal) — Its strongest rationale is as a fear-extinction and therapy-alliance catalyst dosed before prolonged-exposure sessions — the direction a 2024 augmentation meta-analysis found most promising, though still unproven and appropriate only within supervised research.
How we evaluated
We ranked each peptide strictly by the strength of its human evidence for PTSD specifically, refusing to inflate preclinical or anxiety-only data into PTSD claims. Human RCTs in PTSD patients outrank anxiety trials, which outrank rodent and mechanistic studies, which outrank marketing. Every grade separates what has been shown in people with PTSD from what has only been shown in anxiety, in animals, or in theory.
- Human PTSD trial evidence. Whether the peptide has been tested in actual PTSD patients in randomized controlled trials, and what those trials found on hard clinical endpoints.
- Directness of the evidence. How far the data are from a PTSD outcome — PTSD-patient trials rank above anxiety trials, healthy-volunteer mechanism, and rodent studies.
- Safety in trauma populations. Condition-specific risks such as oxytocin's sympathomimetic and amygdala effects, and unestablished long-term safety for Selank and Semax.
- Regulatory & honesty status. FDA approval status, 503A compounding posture, WADA exposure, and whether marketing claims exceed the evidence.
Rating scale: 1–5 stars reflecting the strength and directness of human PTSD evidence; letter grades (A–D) follow the PeptideVox evidence ramp, where A is human RCT/meta and C–D is preclinical or anecdotal.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | Oxytocin (intranasal) | B | 3.0 | Supervised research augmenting trauma-focused psychotherapy, dosed before prolonged-exposure sessions | Not FDA-approved intranasally; off-label / compounded, varies |
| 2 | Selank | C | 2.5 | Contextual understanding of anxiolytic peptides where hyperarousal and anxiety dominate — not a PTSD treatment | Not FDA-approved; research chemical, varies |
| 3 | Semax | D | 1.5 | Understanding why a cognition/neurology peptide is not a trauma treatment — not for PTSD use | Not FDA-approved; research chemical, varies |
Oxytocin (intranasal)
The only peptide tested in PTSD patients — with genuinely mixed results
Oxytocin earns the top spot because it is the only one of the three actually tested in PTSD patients in randomized trials, though the evidence is mixed and it should be understood as an experimental adjunct under study, not a treatment. The mechanistic foundation is a healthy-volunteer RCT in which 24 IU intranasal oxytocin improved fear-extinction recall 24 hours later, though it transiently increased fear-potentiated startle early in extinction before groups converged. In PTSD patients, a pilot trial augmenting prolonged exposure with 40 IU before each session showed a favorable but non-significant trend, and a crossover trial in 35 women reduced provoked symptoms while simultaneously raising heart rate and sympathetic cardiac drive. The most rigorous study, a prevention RCT in emergency-department patients, was negative on its primary endpoint, with benefit only in a high-baseline-symptom subgroup and imaging showing increased amygdala reactivity in the recently traumatized. A systematic review of fourteen studies concluded oxytocin appears safe but that efficacy data are mixed and insufficient to quantify. The single-dose studies show little; repeated dosing plus psychotherapy augmentation is the more promising, still unproven direction.
Strengths
- The only peptide with any randomized-trial evidence in actual PTSD patients
- Strong mechanistic support for enhancing fear extinction in healthy-volunteer RCTs
- Systematic review judged it generally safe at reported intranasal doses
- Most promising direction — psychotherapy augmentation — aligns with first-line PTSD care
Weaknesses
- Well-powered prevention RCT was negative on its primary endpoint
- Raised heart rate and sympathetic drive, and increased amygdala reactivity acutely after trauma — not reliably calming
- Intranasal formulation is not FDA-approved; approved oxytocin (Pitocin) is IV obstetric only
- Overall efficacy in PTSD is mixed and insufficient to quantify
- Best for
- Supervised research augmenting trauma-focused psychotherapy, dosed before prolonged-exposure sessions
- Pricing
- Not FDA-approved intranasally; off-label / compounded, varies
Source: Giovanna et al., systematic review of intranasal oxytocin in PTSD, 2020
Selank
Real human RCT evidence — but for anxiety, not PTSD
Selank ranks second because it has genuine human RCT evidence, but for generalized anxiety disorder and neurasthenia rather than PTSD, so treating it as a trauma peptide is an extrapolation from its anxiolytic profile to PTSD's hyperarousal symptoms. The key human study is a 62-patient Russian trial in which Selank 450 mcg intranasally three times daily for 14 days produced anxiolytic efficacy comparable to the benzodiazepine medazepam on Hamilton, Zung and CGI scales, with added antiasthenic effects and without benzodiazepine-type sedation, tolerance or withdrawal. The important caveat is that this is a Russian-language report whose English abstract gives no p-values, effect sizes or responder rates, and it has not been independently replicated in Western trials. Mechanistically, Selank appears to act through allosteric GABA-A modulation and enkephalinase inhibition, and in a chronic-mild-stress rat model it enhanced the anxiolytic effect of diazepam — preclinical support for stress buffering, not human PTSD efficacy. No PTSD trial of Selank exists in the indexed literature, so its evidence is Grade B for anxiety but downgrades to C or D for PTSD itself. There are no long-term human safety data and no formal interaction studies with psychiatric medications.
Strengths
- Genuine human RCT evidence — anxiolytic efficacy comparable to a benzodiazepine in GAD/neurasthenia
- Reported without benzodiazepine-type sedation, tolerance or withdrawal
- Coherent GABAergic and enkephalinase mechanism relevant to hyperarousal
- Preclinical stress-buffering support in a chronic-mild-stress rat model
Weaknesses
- No PTSD trials exist — all human data are for anxiety/neurasthenia, not trauma
- Evidence confined to a single small Russian research tradition, unreplicated in the West
- No long-term human safety data and no formal SSRI/SNRI/benzodiazepine interaction studies
- Not FDA-approved; sold as a research chemical
- Best for
- Contextual understanding of anxiolytic peptides where hyperarousal and anxiety dominate — not a PTSD treatment
- Pricing
- Not FDA-approved; research chemical, varies
Source: Zozulia et al., Selank vs medazepam in GAD/neurasthenia, 2008
Semax
No PTSD human data — evidence is in cognition and stroke
Semax ranks last because, despite being marketed alongside Selank for trauma and mood, it has no human PTSD or trauma trials, and its PTSD relevance is purely mechanistic and marketing-driven. Its legitimate human evidence is for cognition and neurological recovery: a healthy-volunteer fMRI study found that intranasal 1% Semax acutely altered default-mode-network activity in the medial prefrontal cortex within 5 to 20 minutes, a cognition and neuro-modulation signal rather than a mood or PTSD outcome. In Russia, Semax is a registered drug used for stroke recovery, traumatic brain injury and cognitive indications, with human data concentrated in those areas and largely Russian-language; no qualifying Western PTSD trials exist. Mechanistically, Semax is an ACTH4-10 analog that upregulates BDNF and TrkB and is neurotrophic and neuroprotective in rodent models, including disease models. This grounds the resilience and neuroplasticity narrative but says nothing about PTSD symptom reduction in people. For PTSD the evidence is animal and mechanistic at best, shading into marketing claims, so it is Grade C to D for this condition. Human safety data outside Russian neurology use are limited, and it is not FDA-approved in the United States.
Strengths
- Legitimate human evidence exists — for cognition and stroke recovery, not PTSD
- Coherent BDNF/TrkB neurotrophic mechanism in rodent models
- Registered and used clinically in Russia for neurological indications
- Acute human fMRI signal on default-mode-network / prefrontal activity
Weaknesses
- No human PTSD or trauma trials of any kind exist
- PTSD claims rest entirely on rodent BDNF mechanisms — Grade C–D for this condition
- Human evidence is largely Russian-language and confined to cognition/neurology
- Not FDA-approved; sold as a research chemical with limited safety characterization
- Best for
- Understanding why a cognition/neurology peptide is not a trauma treatment — not for PTSD use
- Pricing
- Not FDA-approved; research chemical, varies
Source: Semax & the brain default mode network, human fMRI study, 2018
Feature comparison
| Feature | Oxytocin (intranasal) | Selank | Semax |
|---|---|---|---|
| Tested in PTSD patients | ✓ | — | — |
| Human RCT evidence | Yes (PTSD; mixed) | Yes (anxiety only) | No (cognition/stroke only) |
| Directness to PTSD outcome | Direct (PTSD-patient trials) | Indirect (anxiety extrapolation) | Mechanistic/rodent only |
| Feature | Oxytocin (intranasal) | Selank | Semax |
|---|---|---|---|
| FDA-approved for PTSD | — | — | — |
| Long-term human safety data | Limited | None | Limited |
| WADA/regulatory exposure | Approved IV only (Pitocin) | Unapproved; S0 risk | Unapproved; S0/S2 risk |
Frequently asked
Is any peptide FDA-approved to treat PTSD?
No. None of intranasal oxytocin, Selank, or Semax is FDA-approved for PTSD. The only FDA-approved oxytocin product is Pitocin, an intravenous obstetric drug for labor and postpartum hemorrhage, not a PTSD medication, and the intranasal spray is unapproved in the United States. Selank and Semax are not FDA-approved for any indication and are sold as research chemicals. First-line, evidence-based PTSD care remains trauma-focused psychotherapy such as prolonged exposure, cognitive processing therapy and EMDR, with SSRIs or SNRIs as a secondary option. Any peptide use for PTSD is off-label and experimental.
Does oxytocin actually reduce PTSD symptoms?
Sometimes, but inconsistently. Small studies show benefit on provoked symptoms in female PTSD patients, and a pilot trial augmenting prolonged exposure showed a favorable trend that did not reach statistical significance. However, the most rigorous prevention trial, which dosed emergency-department patients soon after trauma, was negative on its primary endpoint, and companion imaging found oxytocin increased amygdala reactivity in recently traumatized people. A systematic review of fourteen studies judged the evidence mixed and insufficient to quantify effectiveness. Oxytocin is best understood as an experimental adjunct under study, not a proven treatment.
If Selank treats anxiety, doesn't that mean it treats PTSD?
No, that is an extrapolation rather than evidence. Selank's human randomized-trial data are for generalized anxiety disorder and neurasthenia, come from a single small Russian research tradition, and have not been independently replicated in Western trials. No PTSD trial of Selank exists in the indexed literature. PTSD is a distinct disorder involving impaired fear extinction, amygdala hyperreactivity and re-experiencing, not just baseline anxiety. Relieving anxiety might in theory help PTSD's hyperarousal symptoms, but that mechanistic plausibility is several inferential steps away from demonstrated efficacy. For PTSD specifically, Selank's evidence is Grade C to D.
Why is Semax ranked lowest if it's a well-known brain peptide?
Because its legitimate human evidence is for cognition and stroke recovery, not trauma. The one human study cited here is a healthy-volunteer fMRI study of default-mode-network activity, a cognition and neuro-modulation signal rather than a mood or PTSD outcome. In Russia, Semax is a registered drug used for stroke, traumatic brain injury and cognitive indications, but no qualifying Western PTSD trials exist. Its PTSD relevance rests entirely on rodent studies showing BDNF upregulation, which grounds a resilience and neuroplasticity narrative but says nothing about PTSD symptom reduction in people. That makes it Grade C shading into D for this condition.
Is oxytocin a calming trauma fix?
Not reliably. Oxytocin is often marketed as a soothing prosocial hormone, but in trauma populations it is not dependably calming. In female PTSD patients it reduced some provoked symptoms while simultaneously raising heart rate and increasing sympathetic cardiac drive, a sympathomimetic effect that matters in an already hyperaroused population. In the prevention trial, oxytocin increased amygdala reactivity in recently traumatized people, meaning it may not be uniformly beneficial and could be counterproductive in some trauma states. Its effects are state- and context-dependent, which is a central reason it belongs in supervised research rather than self-experimentation.
Are these peptides safe to buy online and self-administer for trauma?
No. Selank and Semax are sold as unregulated research chemicals, often labeled not for human use, with documented purity and sterility risks including contamination and mislabeling that formed part of the FDA's stated safety rationale. Oxytocin has documented cardiovascular effects in PTSD patients and may increase amygdala reactivity acutely after trauma. None of the three has long-term human PTSD safety data. Long-term safety for Selank and Semax is unestablished, and there are no formal interaction studies with SSRIs, SNRIs or benzodiazepines. The responsible path is to work with a licensed clinician and prioritize proven, evidence-based therapy.